The China Drug Administration Proposes a Working Procedure for Pharmaceutical Study Data Protection

Published date08 May 2018
Law FirmRopes & Gray LLP
AuthorKatherine Wang
Subject MatterData Protection,China,Regulatory Agenda,Generic Drugs,China FDA,Pharmaceutical Industry,Marketing Authorization Application

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT